Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

Oneness Biotech

Status and phase

Completed

Phase 3

Conditions

Diabetic Foot

Treatments

Other: Aquacel® Hydrofiber® dressing

Drug: ON101 Cream

Study type

Interventional

Funder types

Industry

Identifiers

NCT01898923

ON101CLCT02

Details and patient eligibility

About

The primary objective of this study is to evaluate the efficacy of the new treatment of WH-1 ointment compared to Aquacel® Hydrofiber® dressing, applied to chronic diabetic foot ulcers for up to 16 weeks.An additional objective of this study is to collect safety information including adverse events and clinical laboratory abnormalities.

Full description

This trial is designed as a randomized, evaluator blinded, active-controlled, multi-center study comparing the efficacy and safety of WH-1 ointment and Aquacel® Hydrofiber® dressing in the treatment of diabetic foot ulcers. Independent evaluators who blinded to subjects' treatment will evaluate whether the wound has healed. Eligible subjects will be randomized to receive either WH-1 ointment or Aquacel® Hydrofiber® dressing in a 1:1 allocation. The study treatment will be applied to the selected ulcer for a maximum period of 16 weeks, until the wound/ulcer closure (wound size of 0) for two consecutive visits at least 2 weeks apart, or until the subject exited the study as treatment failure. After that, all subjects regardless of wound healing at the end of comparison period will be followed for 12 weeks to investigate durability. During the follow-up period, Aquacel® Hydrofiber® dressing will be applied for subjects who have unhealed or with recurrent wound. Each target ulcer with wound photographs for blind assessment will be monitored at each scheduled visit.

One interim analysis is planned at around 50% of study information; the final analysis will be conducted at the end of the study.

Enrollment

236 patients

Sex

All

Ages

20 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Has signed a written informed consent prior to the first study evaluation;
Male or female is at least 20 and < 80 years of age;
Diabetes mellitus (type 1 or 2) with an HbA1c < 12.0% measured during screening or within three months prior to randomization;
An ankle brachial index on the target limb at least 0.8 measured during screening or within three months prior to randomization;
The target ulcer must have the following characteristics:
- Grade 1 or 2 per Wagner Ulcer Classification System;
- No higher than the ankle;
- No active infected;
- A cross-sectional area of between 1 and 25 cm2 post-debridement;
- Present for at least 4 weeks before randomization;
If female and of childbearing potential has a negative pregnancy test and is not breastfeeding at screening visit;
Able and willing to attend the scheduled visits and comply with study procedures.

Exclusion Criteria:

Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement;
Acute Charcot's neuroarthropathy as determined by clinical and/or radiographic examination;
Has undergone revascularization procedure aimed at increasing blood flow in the treatment target limb < 4 weeks prior to randomization;
Poor nutritional status defined as an albumin < 2.5 g/dL;
Aspartate Aminotransferase(AST, GOT) and/or Alanine Aminotransferase(ALT, GPT) >3 x the normal upper limit;
Serum Creatinine >2 x the normal upper limit;
Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 4 weeks before randomization;
Use of any investigational drug or therapy within the 4 weeks prior to randomization;
A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug abuse problem, determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance;
Judged by the investigator not to be suitable for the study for any other reason.